Structure Therapeutics Inc.’s GPCR share price has dipped by 12.27%, which has investors questioning if this is right time to buy.

American Century Companies Inc. increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has been given an average rating of “Buy” by the eight research ...

G Protein-Coupled Receptors (GPCRs) in advancing GPCR-targeted therapies, including the use of agonists, antagonists, biased ...

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. A mere six months ago Verily ...

Septerna, Inc. ( ($SEPN) ) has released its Q4 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors.

Exicure (XCUR) announced that the Australian Patent Office has issued Patent No. 2018388302, titled “GPCR Heteromer Inhibitors and Uses ...